Evidence map›Paper›PMID 24151433›Full record

ArticleInternational journal of medical sciences2013

Interaction of RAS activation and lipid disorders accelerates the progression of glomerulosclerosis.

Kun-Ling Ma, Jie Ni, Chang-Xian Wang, Jing Liu, Yang Zhang, Yu Wu, Lin-Li Lv, Xiong-Zhong Ruan, Bi-Cheng Liu

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in International journal of medical sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Kun-Ling Ma1. Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing City, Jiangsu Province, P.R. China.
Jie Ni
Chang-Xian Wang
Jing Liu
Yang Zhang
Yu Wu
Lin-Li Lv
Xiong-Zhong Ruan
Bi-Cheng Liu
Zhongda Hospital Southeast University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe activation of the renin-angiotensin system (RAS) and lipid disorders are major risk factors in progressive chronic kidney disease. This study aimed to investigate the potential synergistic mechanisms of RAS activation and lipid disorders that contribute to glomerulosclerosis. MATERIALS AND

methodsHuman renal mesangial cells (HMCs) were treated with 10(-7) mol/L angiotensin II (Ang II) or with 30 μg/ml cholesterol and 1 μg/ml 25-hydroxycholesterol (lipid loading) for 24 hours. Lipid accumulation in the cells was evaluated by Oil Red O staining and intracellular cholesterol quantitative assays. The gene and protein expression of molecules in the low-density lipoprotein receptor (LDLr) pathway, the RAS family, and the extracellular matrix were examined by real-time polymerase chain reaction and Western blotting. The translocation of sterol regulatory element-binding protein (SREBP) cleavage activating protein (SCAP), which escorts SREBP-2 from the endoplasmic reticulum (ER) to the Golgi, was examined by immunofluorescent staining.

resultsAng II increased lipid droplet accumulation in HMCs. Further analysis revealed that Ang II increased the mRNA and protein expression of LDLr, SCAP, and SREBP-2. This increase was correlated with an enhanced translocation of the SCAP/SREBP-2 complex from the ER to the Golgi in HMCs that was induced by Ang II, thereby activating LDLr gene transcription. Interestingly, lipid loading increased the mRNA and protein expression of angiotensinogen, Ang II, renin, angiotensin-converting enzyme, angiotensin II type 1 receptor, and type 2 receptor in HMCs with increased mRNA and protein expression of collagen I, α-smooth muscle actin, and fibronectin.

conclusionsThis study demonstrates that the interaction of RAS activation and lipid disorders accelerates the progression of glomerulosclerosis.

Indexed as

Angiotensin IICholesterolDiabetic NephropathiesDisease ProgressionEndoplasmic ReticulumGene Expression RegulationHumansHydroxycholesterolsIntracellular Signaling Peptides and ProteinsLipid MetabolismMembrane ProteinsMesangial Cellsras ProteinsReceptor, Angiotensin, Type 1Receptors, LipoproteinRenin-Angiotensin System25-hydroxycholesterolAngiotensin IICholesterolHydroxycholesterolsIntracellular Signaling Peptides and ProteinsMembrane Proteinsras ProteinsReceptor, Angiotensin, Type 1Receptors, LipoproteinSREBF2 protein, humanSREBP cleavage-activating proteinSterol Regulatory Element Binding Protein 2Sterol Regulatory Element Binding Proteinsextracellular matrixglomerulosclerosislipid disorderlow-density lipoprotein receptorrenin-angiotensin system

Identifiers

PMID24151433
PMCPMC3804787
OpenAlexW2009748563

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.